Ironwood Pharmaceuticals Analyst Ratings
Ironwood Pharmaceuticals Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/16/2022 | 9.15% | Wells Fargo | $12 → $13 | Maintains | Equal-Weight |
04/22/2022 | 34.34% | Piper Sandler | → $16 | Initiates Coverage On | → Overweight |
10/12/2021 | 17.55% | Morgan Stanley | $13 → $14 | Maintains | Equal-Weight |
07/16/2021 | 0.76% | Morgan Stanley | $11 → $12 | Maintains | Equal-Weight |
02/22/2021 | -7.64% | Morgan Stanley | $12 → $11 | Maintains | Equal-Weight |
02/19/2021 | -7.64% | Morgan Stanley | $12 → $11 | Maintains | Equal-Weight |
11/06/2020 | 0.76% | Credit Suisse | $11 → $12 | Maintains | Neutral |
11/06/2020 | 0.76% | Morgan Stanley | $11 → $12 | Maintains | Equal-Weight |
09/30/2020 | -24.43% | Wells Fargo | → $9 | Downgrades | Overweight → Equal-Weight |
08/07/2020 | -7.64% | Morgan Stanley | $10 → $11 | Maintains | Equal-Weight |
07/15/2020 | -16.04% | Morgan Stanley | $11 → $10 | Maintains | Equal-Weight |
06/01/2020 | -7.64% | Credit Suisse | $12 → $11 | Maintains | Neutral |
05/11/2020 | -7.64% | HC Wainwright & Co. | $13 → $11 | Reiterates | → Neutral |
05/07/2020 | -7.64% | Morgan Stanley | $12 → $11 | Maintains | Equal-Weight |
04/30/2020 | 25.94% | Wells Fargo | $16 → $15 | Maintains | Overweight |
04/15/2020 | 0.76% | Morgan Stanley | $13 → $12 | Maintains | Equal-Weight |
07/10/2019 | — | Credit Suisse | Assumes | → Neutral | |
03/27/2019 | 17.55% | Morgan Stanley | $11 → $14 | Upgrades | Underweight → Equal-Weight |
02/25/2019 | 17.55% | HC Wainwright & Co. | $11.5 → $14 | Upgrades | Sell → Neutral |
01/24/2019 | 9.15% | JP Morgan | $11 → $13 | Upgrades | Underweight → Neutral |
11/07/2018 | — | JP Morgan | Downgrades | Neutral → Underweight | |
11/07/2018 | — | Credit Suisse | Downgrades | Outperform → Neutral | |
08/09/2018 | 93.12% | Wells Fargo | $22 → $23 | Maintains | Outperform |
07/23/2018 | 4.95% | HC Wainwright & Co. | → $12.5 | Initiates Coverage On | → Sell |
07/18/2018 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
05/31/2018 | 67.93% | Wells Fargo | $18 → $20 | Maintains | Outperform |
05/09/2018 | — | Morgan Stanley | Downgrades | Equal-Weight → Underweight | |
05/03/2018 | 67.93% | Barclays | $16 → $20 | Maintains | Equal-Weight |
05/02/2018 | — | Mizuho | Upgrades | Neutral → Buy | |
01/05/2018 | — | B of A Securities | Downgrades | Buy → Underperform | |
12/06/2017 | — | Mizuho | Downgrades | Buy → Neutral | |
11/27/2017 | 59.53% | Credit Suisse | → $19 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
08/16/2022 | 9.15% | 富國銀行 | 12 美元 → 13 美元 | 維護 | 重量相等 |
04/22/2022 | 34.34% | 派珀·桑德勒 | → 16 美元 | 啓動覆蓋範圍開啓 | → 超重 |
2021 年 12 月 10 日 | 17.55% | 摩根士丹利 | 13 美元 → 14 美元 | 維護 | 重量相等 |
07/16/2021 | 0.76% | 摩根士丹利 | 11 美元 → 12 美元 | 維護 | 重量相等 |
2021 年 2 月 22 日 | -7.64% | 摩根士丹利 | 12 美元 → 11 美元 | 維護 | 重量相等 |
02/19/2021 | -7.64% | 摩根士丹利 | 12 美元 → 11 美元 | 維護 | 重量相等 |
11/06/2020 | 0.76% | 瑞士信貸 | 11 美元 → 12 美元 | 維護 | 中立 |
11/06/2020 | 0.76% | 摩根士丹利 | 11 美元 → 12 美元 | 維護 | 重量相等 |
09/30/2020 | -24.43% | 富國銀行 | → 9 美元 | 降級 | 超重 → 重量相等 |
08/07/2020 | -7.64% | 摩根士丹利 | 10 美元 → 11 美元 | 維護 | 重量相等 |
07/15/2020 | -16.04% | 摩根士丹利 | 11 美元 → 10 美元 | 維護 | 重量相等 |
06/01/2020 | -7.64% | 瑞士信貸 | 12 美元 → 11 美元 | 維護 | 中立 |
05/11/2020 | -7.64% | HC Wainwright & Co. | 13 美元 → 11 美元 | 重申 | → 中立 |
05/07/2020 | -7.64% | 摩根士丹利 | 12 美元 → 11 美元 | 維護 | 重量相等 |
04/30/2020 | 25.94% | 富國銀行 | 16 美元 → 15 美元 | 維護 | 超重 |
2020 年 4 月 15 日 | 0.76% | 摩根士丹利 | 13 美元 → 12 美元 | 維護 | 重量相等 |
2019 年 10 月 7 日 | — | 瑞士信貸 | 假設 | → 中立 | |
03/27/2019 | 17.55% | 摩根士丹利 | 11 美元 → 14 美元 | 升級 | 體重不足 → 重量相等 |
02/25/2019 | 17.55% | HC Wainwright & Co. | 11.5 美元 → 14 美元 | 升級 | 賣出 → 中立 |
2019 年 1 月 24 日 | 9.15% | 摩根大通 | 11 美元 → 13 美元 | 升級 | 體重不足 → 中性 |
11/07/2018 | — | 摩根大通 | 降級 | 中性 → 體重不足 | |
11/07/2018 | — | 瑞士信貸 | 降級 | 跑贏大盤 → 中性 | |
2018 年 9 月 8 日 | 93.12% | 富國銀行 | 22 美元 → 23 美元 | 維護 | 跑贏大盤 |
2018 年 7 月 23 日 | 4.95% | HC Wainwright & Co. | → 12.5 美元 | 啓動覆蓋範圍開啓 | → 賣出 |
07/18/2018 | — | Cowen & Co. | 降級 | 跑贏大盤 → 市場表現 | |
05/31/2018 | 67.93% | 富國銀行 | 18 美元 → 20 美元 | 維護 | 跑贏大盤 |
2018 年 9 月 5 日 | — | 摩根士丹利 | 降級 | 等重 → 減重 | |
05/03/2018 | 67.93% | 巴克萊 | 16 美元 → 20 美元 | 維護 | 重量相等 |
05/02/2018 | — | 瑞穗市 | 升級 | 中性 → 買入 | |
01/05/2018 | — | B of A 類證券 | 降級 | 買入 → 表現不佳 | |
2017 年 6 月 12 日 | — | 瑞穗市 | 降級 | 買入 → 中性 | |
11/27/2017 | 59.53% | 瑞士信貸 | → 19 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
Ironwood Pharmaceuticals Questions & Answers
艾恩伍德製藥問答
The latest price target for Ironwood Pharmaceuticals (NASDAQ: IRWD) was reported by Wells Fargo on August 16, 2022. The analyst firm set a price target for $13.00 expecting IRWD to rise to within 12 months (a possible 9.15% upside). 3 analyst firms have reported ratings in the last year.
富國銀行於2022年8月16日公佈了艾恩伍德製藥(納斯達克股票代碼:IRWD)的最新目標股價。該分析公司將目標股價定爲13.00美元,預計IRWD將在12個月內升至12個月內(可能上漲9.15%)。去年有3家分析公司公佈了評級。
The latest analyst rating for Ironwood Pharmaceuticals (NASDAQ: IRWD) was provided by Wells Fargo, and Ironwood Pharmaceuticals maintained their equal-weight rating.
富國銀行對艾恩伍德製藥(納斯達克股票代碼:IRWD)的最新分析師評級由富國銀行提供,艾恩伍德製藥維持同等權重評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ironwood Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ironwood Pharmaceuticals was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Ironwood Pharmicals的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Ironwood Pharmicals的最新評級是在2022年8月16日公佈的,因此您應該預計下一個評級將在2023年8月16日左右公佈。
While ratings are subjective and will change, the latest Ironwood Pharmaceuticals (IRWD) rating was a maintained with a price target of $12.00 to $13.00. The current price Ironwood Pharmaceuticals (IRWD) is trading at is $11.91, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的鐵木製藥(IRWD)評級維持不變,目標股價爲12.00美元至13.00美元。艾恩伍德製藥(IRWD)目前的交易價格爲11.91美元,超出了分析師的預期區間。